| Literature DB >> 33897888 |
Yao Tong1, Huiru Gao1, Qiuchen Qi1, Xiaoyan Liu1, Juan Li1, Jie Gao1, Peilong Li1, Yunshan Wang1, Lutao Du1, Chuanxin Wang1,2,3.
Abstract
Gastrointestinal cancer is currently one of the main causes of cancer death, with a large number of cases and a wide range of lesioned sites. A high fat diet, as a public health problem, has been shown to be correlated with various digestive system diseases and tumors, and can accelerate the occurrence of cancer due to inflammation and altered metabolism. The gut microbiome has been the focus of research in recent years, and associated with cell damage or tumor immune microenvironment changes via direct or extra-intestinal effects; this may facilitate the occurrence and development of gastrointestinal tumors. Based on research showing that both a high fat diet and gut microbes can promote the occurrence of gastrointestinal tumors, and that a high fat diet imbalances intestinal microbes, we propose that a high fat diet drives gastrointestinal tumors by changing the composition of intestinal microbes. © The author(s).Entities:
Keywords: gastrointestinal cancer; gut microbiome; high fat diet; inflammation; metabolic reprogramming
Year: 2021 PMID: 33897888 PMCID: PMC8058730 DOI: 10.7150/thno.56157
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 1Association of HFD with gastrointestinal cancers. High fat diet can cause metabolic reprogramming in multiple organs and tissues of the human body with alterations in the content of various regulatory factors. It mainly acts on tumor cells themselves, nearby tissues and tumor microenvironment. The molecules marked in red are upregulated, while green downregulated. GGPPS: Geranylgeranyl diphosphate synthase.
Effects of high fat diet on intestinal microorganisms and body
| No. | Specimen type | Specimen Source | Technology | Microbial composition alteration | Metabolites and other alterations | First author, year |
|---|---|---|---|---|---|---|
| 1 | Mucosal and luminal contents | C57BL/6J mice | Whole-genome shotgun sequencing, 16S rRNA gene amplification | Order level: ↑ | — | Kim M.S., 2016 |
| 2 | Fecal samples | Rat | Pyrosequencing technology, NMR | ↑ | ↑Fecal tyrosine and phenylalanine. | Lin H., 2016 |
| 3 | Fecal samples | C57BL/6 mice | 16S rRNA sequencing | Phylum level: ↑ | ↑Plasma: leptin, TNFα, IL-6. | Zeng H., 2016 |
| 4 | Fecal samples | C57BL/6J mice, 129S6/Sv mice | HiSeq-based whole genome sequencing | Genus level: ↑ | ↑Genes expression involved in pathways and modules related to fatty acid metabolism, cell mobility, transport, methane metabolism, and xenobiotic degradation; capacity for glycerol utilization of the gut microbiota. | Xiao L., 2017 |
| 5 | Intestinal contents | C57BL/6 mice | Real-time PCR | Genus level: ↑ | ↑Intestinal inflammatory cytokines including TNF-α, IL-1β, and IL-6. ↑Serum IFNγ and TNF-α. | Guo X, 2017 |
| 6 | Cecal contents | C57BL/6J, 129S1/SvImJ and 129S6/SvEvTac mice | 16S rRNA sequencing | Phylum level: ↑ | ↑Cecum: bile acids, AMP, cAMP, ADP, and CMP and nucleosides; plasma: proinflammatory fatty acids, such as adrenic and stearic acid. | Fujisaka S., 2018 |
| 7 | Fecal samples | Mice | 16S rRNA sequencing | Order level: ↑ | ↑Serum: triglyceride, cholesterol, and high density lipoprotein; membrane transport and carbohydrate metabolism. ↓Adipose tissue: genes related to lipid metabolism expression such as PPARɑ/γ, LXRɑ/β; | Yin J., 2018 |
| 8 | Cecum contents | Hens | 16S rRNA gene amplification, pyrosequencing | Family level: ↑ | ↑TC, TG, low-density lipoprotein cholesterol | Liu C., 2018 |
| 9 | Faecal samples | Young adults | 16S rRNA sequencing | Genus level: ↑ | ↑Four pathways: steroid hormone biosynthesis, lysosome pathway, arachidonic acid metabolism and lipopolysaccharide biosynthesis. | Wan Y., 2019 |
↑: Increased; ↓: Decreased.
Figure 2Association of intestinal microbiomes with gastrointestinal cancers. Intestinal microbes mainly through their bacteria or secreted metabolite components that lead to the development of gastrointestinal tumors.
Intestinal microbial action on cancer mechanism
| No. | Types of cancer | Intestinal microbes | Molecules | Tumor promoter or suppressor | Mechanism | First author, year |
|---|---|---|---|---|---|---|
| 1 | Colon cancer | Promoter | Kostic A.D., 2013 | |||
| 2 | Colon cancer | Promoter | Fap2 protein of | Gur C., 2015 | ||
| 3 | Colon cancer | Promoter | Mima K., | |||
| 4 | Colon cancer | Fap2 (fusobacterial lectin) | Promoter | Fap2 mediates attachment of | Abed J., 2016 | |
| 5 | Colon cancer | Promoter | Yang Y., 2017 | |||
| 6 | Colon cancer | Promoter | Rubinstein M.R., 2019 | |||
| 7 | Colon cancer | Promoter | Colibactin-producing | Cougnoux A., 2014 | ||
| 8 | Colon cancer | Promoter | Colon cancer-associated | Raisch J.,2015 | ||
| 9 | Colon cancer | Promoter | ETBF-triggered colon tumorigenesis is associated with an IL-17-driven myeloid signature characterized by subversion of steady-state myelopoiesis in favor of the generation of protumoral monocytic-MDSCs. | Thiele Orberg E., 2017 | ||
| 10 | Colon cancer | Promoter | BFT triggers a pro-carcinogenic, multi-step inflflammatory cascade requiring IL-17R, NF-κB, and Stat3 signaling in colonic epithelial cells. | Chung L., 2018 | ||
| 11 | Colon cancer | (1) | Suppressor; promoter; promoter | (1) | Daniel S.G., 2017 | |
| 12 | Colon cancer | Commensal gut fungi | Suppressor | Commensal gut fungi mediate inflammasome activation by SYK-CARD9 Signaling Axis to restrict colon cancer. | Malik A., 2018 | |
| 13 | Colon cancer | Sirtuin-3 (Sirt3) | Suppressor | Gut microbiota (mainly | Zhang Y., 2018 | |
| 14 | Colon cancer | Cytolethal distending toxin | Promoter | He Z., 2019 | ||
| 15 | Colon cancer | P-cresol | Promoter | Exogenous p-cresol further increased DNA damage, and independently p-cresol induced DNA damage in a dose-dependent manner against HT29 and Caco-2 cells and influenced cell cycle kinetics. | Al Hinai E.A., 2019 | |
| 16 | Colon cancer | Flagellin (microbial componments) | Promoter | Flagellin increase IL6 and CCL2/MCP-1 mRNA and IL6 excretion and cytotoxicity, decrease caspase-1 activity and the production of reactive oxygen species of CRC cells. | Pekkala S., 2019 | |
| 17 | Colon cancer liver metastasis | Lipopolysaccharide (microbial componments) | promoter | LPS promote CRC metastasis by stimulating TLR4 signaling and increasing β1 integrin-mediated cell adhesion. | Hsu R.Y., 2011 | |
| 18 | Colon cancer liver metastasis | Lipopolysaccharide (microbial componments) | Promoter | Trapping LPS reduced liver metastasis of primary CRC and attenuated metastasized tumor growth in the liver. | Song W., 2018 | |
| 19 | Gastric | Promoter | The gastric carcinoma microbiota is dysbiotic and characterised by reduced microbial diversity, reduced | Ferreira RM, 2018 | ||
| 20 | Gastric cancer | P-cresol (microbial metabolites) | Promoter | Wroblewski LE, 2015 | ||
| 21 | Gastric cancer | CagPAI | Promoter | EMT-like morphological changes, specifically induced by cagPAI+ | Jessica Baud, 2013 | |
| 22 | Gastric cancer | CagA | Promoter | Degradation of p53 induced by bacterial CagA protein is mediated by host HDM2 and ARF-BP1 E3 ubiquitin ligases, while the p14ARF protein counteracts | Jinxiong Wei, 2015 | |
| 23 | Gastric cancer | Bacterial overgrowth | Promoter | Wang, 2016 | ||
| 24 | Gastric cancer | LAB, oral bacterial species | SCFA, lactic | Promoter | 16S rRNA transcript sequencing | Castaño-Rodriguez, 2017 |
| 25 | Liver cancer | Bile acids | Promoter | The altered gut microbiota causes sustained retention of high concentrations of hepatic bile acids, and then promote liver carcinogenesis. | Xie G., 2016 | |
| 26 | Liver cancer | Lipoteichoic acid (microbial componments) deoxycholic acid (microbial metabolites) | Promoter | Deoxycholic acid and lipoteichoic acid derived from the gram-positive gut microbiota cooperated to upregulate the expression of SASP factors and COX2 in DCA-induced senescent hepatic stellate cells through TLR2. | Loo T.M., 2017 | |
| 27 | Liver cancer | Bile acid | Suppressor/promoter | Primary bile acids increases CXCL16 expression, which recruits CXCR6+ natural killer T cells to the liver, and mediate liver tumor inhibition, whereas secondary bile acids showed the opposite effect. | Ma C., 2018 | |
| 28 | Liver cancer | SCFA-producing bacteria | SCFA (microbial metabolites) | promoter | Dietary soluble fibers are fermented by gut bacteria into SCFAs, which promotes hepatocyte proliferation, liver fibrosis and induces cholestatic liver cancer. | Singh V., 2018 |
| 29 | Liver cancer | Interleukin-25 | promoter | Dysbiosis of gut microbiota results in secretion of IL-25, which promotes the progression of HCC through inducing alternative activation and CXCL10 secretion of macrophages in tumor microenvironment. | Li Q., 2019 | |
| 30 | Breast | Lithocholic acid (microbial metabolites) | Suppressor | Lithocholic acid can limit the proliferation of breast cancer cells | Mikó E., 2018 | |
| 31 | Breast | Gut microbiome | Promoter | Commensal dysbiosis promoted early inflammation within the mammary gland, enhanced fibrosis and collagen deposition both systemically and locally within the tumor microenvironment and induced significant myeloid infiltration into the mammary gland and breast tumor. | Buchta Rosean C., 2019 | |
| 32 | Breast | Lithocholic acid | Suppressor | Lithocholic acid decreases nuclear factor E2-related factor 2 expression, increases KEAP1 expression via activation of TGR5 and constitutive androstane receptor, elicits oxidative stress that slows down the proliferation of breast cancer cells. | Kovács P., 2019 | |
| 33 | Breast | Cadaverine (microbial metabolites) | Suppressor | Cadaverine exerts fuctions through trace amino acid receptors to reduce breast cancer metastasis and induce a mesenchymal-to-epithelial transition and invasion. | Kovács T., 2019 | |
| 34 | Pancreatic cancer | Gut microbiome | Promoter | Gut microbiome interacts with immune system and affects cancer progression, gut microbiome depletion causes a significant anti-tumor influence in TME, such as increase in Th1 and Tc 1 cells. | Sethi V., 2018 | |
| 35 | Pancreatic cancer | Promoter | A distinct gut microbiome was associated with immunogenic reprogramming of the PDAC tumor microenvironment. | Pushalkar S., 2018 | ||
| 36 | Pancreatic cancer | Promoter | Aykut B., 2019 | |||
| 37 | Esophagus cancer | Bile acids | Promoter | Bile acids exposed mice were easier to developed EAC and Barrett esophagus, with acute and chronic immune response, activate differential gene expression and expansion of gastric cardia progenitor cells. | Quante M., 2012 | |
| 40 | Esophagus cancer | Gut microbiome | Promoter | HFD promoted dysplasia by altering the esophageal micro-environment and gut microbiome, thereby inducing inflammation and stem cell expansion. | Münch N.S., 2019 | |
| 41 | Lung cancer | Propionate (microbial metabolites) | Suppressor | Propionate inhibited lung cancer cell proliferation by inducing cell cycle arrest, especially in the G2/M phase. It increased cleaved PARP-1 and caspase 3 expression by down- and upregulating survivin and p21. | Kim K., 2019 | |
| 42 | Melanoma | Suppressor | Sivan A., 2015 |
Figure 3High fat diet changes intestinal microbes and then promotes gastrointestinal cancer. (A) Esophageal Cancer: HFD induced intestinal microbiota dybiosis (1) increases the number of Lgr5+ cells in squamocolumnar junction; (2) activates TLR signal, and promotes the activation of IL8, (3) promotes the production of H2S by increasing the abundance of Desulfovibrio spp. and Clostridium Lavalense. H2S upregulates HSP90 to promote the esophageal cancer. (B) Gastric Cancer: Lactic acid bacteria can produce lactic acid, reactive oxygen species, nitrite and other harmful products to promote gastric cancer in a variety of ways like heterogenesis, angiogenesis and etc. Microbiomes like Enterobacterium and Desulfovibrionaceae can stimulate TLRs and induce carcinogenic changes by producing LPS. LPS can also bind to PD-L1 to produce immune escape. (C) Liver Cancer: HFD changes intestinal microbial composition, leading to accumulation of certain bacterial components and metabolites. FGF and bile acids(BAs)can activate corresponding receptors on hepatocytes, trigger key oncogenic pathways then promote proliferation of cancer cells, release of inflammatory factors or DNA damage. bile acids can also activate TLR on hepatic atellate cells leading to immunosuppression. Increased LPS can activate TLR receptors on Kupffer cells to produce IL-1β and promote fibrosis (D) Pancreatic Cancer: HFD induced gut dysbiosis leads to the hyperglycemia, the increased LPS as well as pathogenic microorganisms such as Malassezia and F. nucleatum. These changes cause chronic inflammation, immune suppression, KRAS mutation fibrosis of pancreas through various mechanisms, which promotes the initiation and progression of cancer. (E) Colorectal Cancer: HFD induced gut microbiome dysbiosis including some specific microbes changes such as Collagenolytic microbes, Fusobacterium nucleatum, Parabacteroides distasoni and microbial metabolites for instance bile acids, resulting in activation of carcinogenic pathways, changes of tumor immune microenvironment, DNA damage. There also exist reduction in DCs, MHC class II molecule and SCFAs. The above changes urge the development in colorectal cancer. SCJ: Squamocolumnar junction.